The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2015 ACR/ARHP Annual Meeting: Research Lends Insight Into Osteoporosis Treatment, New Auto-Inflammatory Disease, Scleroderma

2015 ACR/ARHP Annual Meeting: Research Lends Insight Into Osteoporosis Treatment, New Auto-Inflammatory Disease, Scleroderma

March 15, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Osteoclast activity is essential in the maintenance, repair and remodeling of bones.

Osteoclast activity is essential in the maintenance, repair and remodeling of bones.
Gary Carlson/sciencesource.com

SAN FRANCISCO—Post-menopausal women with osteoporosis, previously treated with oral bisphosphonates, had greater increases in bone density when taking denosumab compared with zoledronic acid over a year’s time, according to a study presented at the 2015 ACR/ARHP Annual Meeting.

You Might Also Like
  • 2015 ACR/ARHP Annual Meeting: Genetically Complex Auto-Inflammatory Diseases
  • 2015 ACR/ARHP Annual Meeting: Macrophage Polarization and Its Role in Inflammatory Disease
  • 2015 ACR/ARHP Annual Meeting: Cellular Triggers in Inflammatory Disease
Explore This Issue
March 2016
Also By This Author
  • RheumPACER Dashboard System Aims for Quick Organization of Patient Data

The findings were discussed in the Discovery 2015 plenary session, which focused on new research. In the session, researchers also discussed genetic mutations linked with early-onset auto-inflammatory disease and new findings on the TH17 T cell response in systemic sclerosis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the Bones

In the denosumab (DMAb) study, researchers set out to examine the effectiveness of two alternatives to oral bisphosphonates for osteoporosis.1 Oral bisphosphonates are the most commonly used treatment for the disease, but adherence can be low, and not all patients respond well.

Less frequently dosed bisphosphonates—such as once-a-year zoledronic acid (ZOL)—are an option for patients who are intolerant to or have failed oral bisphosphonates. Patients can move from one bisphosphonate to another, but the benefits of that approach haven’t been shown, said Paul Miller, MD, medical director of the Colorado Center for Bone Research, who presented the findings.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The study included post-menopausal women at least 55 years old who had been on oral bisphosphonates for at least two years, with a bone mineral density T-score of -2.5 or worse and C-terminal telopeptide (CTX) levels, a marker of bone breakdown, of no higher than 500 pg/mL.

Dr. Miller

Dr. Miller

The patients were randomized to the two groups, with 321 in the DMAb group, who were given 60 mg subcutaneously every six months, and 322 in the ZOL group, who were given a once-yearly IV dose of 5 mg of zoledronic acid.

The groups were balanced in terms of age, years since menopause and bone densities.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

After 12 months, lumbar spine bone density—the primary endpoint—had increased by 2.1% more in the DMAb group, or more than double what was seen in the ZOL group (P<0.0001). Significantly greater increases were also seen in bone densities for total hip, femoral neck and 1/3 radius.

Levels of CTX and P1NP, another marker of bone breakdown, rose gradually among those on ZOL, but remained relatively constant among those taking DMAb, Dr. Miller showed.

The number of serious adverse events was similar for the two groups.

“In post-menopausal women with osteoporosis who had received prior oral bisphosphonates for at least two years or more, transitioning to denosumab resulted in significantly greater increases in bone density compared with zoledronic acid at all measured skeletal sites,” Dr. Miller said.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Scleroderma, Systemic Inflammatory Syndromes Tagged With: 2015 ACR/ARHP Annual Meeting, American College of Rheumatology, auto-inflammatory disease, Bisphosphonate, Immunology, Osteoporosis, Research, Scleroderma, TreatmentIssue: March 2016

You Might Also Like:
  • 2015 ACR/ARHP Annual Meeting: Genetically Complex Auto-Inflammatory Diseases
  • 2015 ACR/ARHP Annual Meeting: Macrophage Polarization and Its Role in Inflammatory Disease
  • 2015 ACR/ARHP Annual Meeting: Cellular Triggers in Inflammatory Disease
  • 2015 ACR/ARHP Annual Meeting: Therapies that Target Schnurri-3 Hold Promise for Osteoporosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)